As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
The company reported consolidated revenue of Rs. 172.9 crore and EBITDA of Rs 25.9 crore in FY26
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
Social media emerges as the primary channel for health-related scams, while influencer endorsements and AI-generated content amplify risks for consumers
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
Bolstering neuroscience push with late-stage Tourette therapy
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
Prior to joining Cipla, Gambhir built a strong track record across the pharmaceutical and healthcare sectors.
Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility
Subscribe To Our Newsletter & Stay Updated
